Clinical Trials

Neovascular Age-Related Macular Degeneration (nAMD)

Faricimab (Vabysmo) is a bi-specific anti-body which blocks two components involved in the development of wet AMD. Faricimab is given as an intravitreal injection into the eye. Faricimab has been recently approved by the TGA for use nAMD following a number of successful clinical trials in naïve patients. This study will investigate the efficacy and durability of faricimab therapy in patients with existing wet AMD over a 2-year period

Study locations:
Sydney Retina Clinic, Strathfield Retina Clinic, Eastwood Eye Specialists, Retina Associates Liverpool, Lane Cove Eye Surgery, Adelaide Eye and Retina, Hobart Eye Surgeons, Albury Eye, Hunter Eye Surgeons, City Eye Centre, Retina Specialists Victoria

This study involves delivery of ranibizumab (Lucentis), an anti-VEGF agent, via a port delivery system (PDS). The implant is an intraocular refillable device that is surgically implanted into the study eye, to allow continuous and constant delivery of ranibizumab into the vitreous. Patients will receive a PDS implant refill exchange either every 36 weeks or 24 weeks until end of study.

Study locations:
Sydney Retina Clinic

This is a phase 3 study and will involve the use of high dose Aflibercept (8mg) for those with wet AMD. The aim of the high dose is to extend treatment intervals to 12 or 16 weeks after the initial loading doses.

The CUREOS Clinical Research Network provides research trials, site management and medical writing.